36results about How to "Implement early treatment" patented technology

The invention relates to a kit for detecting in situ hybridization of broad-spectrum cancer, comprising a hybridization probe and a label, and the sequence of the hybridization probe is shown in SEQ ID NO.1. The invention also provides a method for detecting in situ hybridization of TROP-2 gene. In addition, the invention provides the application of the kit in the preparation of medicine for detecting cancers and diseases, and the cancers includes lung cancer, gastric cancer, breast cancer, carcinoma of colon, prostatic cancer, uterine cancer, cancer of pancreas, carcinoma of urinary bladder, pituitary cancer or glioma. The kit provided by the invention has the characteristics of high sensitivity and better particularity. The detecting method of the invention is convenient and simple in operation, and can be generally used and popularized in the hospitals which are above county level.

The invention relates to an in-situ hybridization detection kit for Spink1 (serine peptidase inhibitor, Kazal type 1) genes, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is expressed as SEQ ID No.1. The invention also provides an in-situ hybridization detection method for the Spink1 genes. In addition, the invention also provides application of the kit in preparation of a medicament for detecting prostatic cancer diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity. The detection method is convenient and simple to operate, and can be universally used and popularized in hospitals of above district level.

The invention discloses an in situ hybridization assay kit. The kit comprises a hybridization probe and a label. The invention also discloses a method for assaying microRNA-34 closely related to early-stage pathologic evolution of various cancers through in situ hybridization by using the kit. The method comprises the following steps: (1) under the condition that the hybridization probe and a target sequence can form a stable hybrid complex, contacting the RNA to be assayed in a substrate with the hybridization probe to form the hybrid complex; and (2) assaying the hybrid complex. The kit and assay method disclosed by the invention have the following beneficial effects: the microRNA-34 expression can be assayed on the RNA level and is earlier than the medical imaging and existing clinical biochemical assay indexes, so that real RNA level screening in the early stage of cancerization can be realized; and meanwhile, the assay method is simple and convenient, has low cost and is convenient to popularize and apply in the county and district level hospitals.

The invention discloses an in-situ hybridization detection kit which includes a hybridization probe and a marker. The invention also discloses a method for detecting change of expression of a miR-378 gene, which is closely relative to pathologic evolution in an early stage of gastric cancer cancerization, through the kit in a manner of in-situ hybridization detection. The method includes following steps: (1) on the condition that the hybridization probe and a target sequence can form a stable hybridization complex, contacting a to-be-detected miR-378 in a substrate with the hybridization probe to form the hybridization complex; and (2) detecting the hybridization complex. By means of the kit and the method, an expression quantity of the miR-378 can be detected on a miRNA level. Compared with image medicine and a clinical biochemical detection index in the prior art, The kit and the method can be applied in an earlier stage and can achieve a true RNA-level screening operation during the early stage of cancerization. Meanwhile, the detection method is simple and convenient, is low in cost and is suitable for being popularized in hospitals in counties or districts.

The invention relates to a Maspin gene in-situ hybridization detection kit, which comprises a hybridization probe and markers, wherein the sequence of the hybridization probe is represented by the sequence SEQ ID No.1. The invention also provides a Maspin gene in-situ hybridization detection method and the use of the kit in the preparation of medicaments for detecting breast cancer. The invention has the advantage that the kit provided by the invention has the characteristics of high sensitivity and high specificity. The detection method of the invention is convenient and simple for operation and can be widely used and promoted in district or above hospitals.

The invention relates to an in situ hybridization detection kit for a human epidermal growth factor receptor-2 (HER-2) gene. The kit comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID NO.1. The invention also provides an in situ hybridization detection method for the Heparinase gene. In addition, the invention also provides the application of the kit in preparing medicaments for detecting diseases such as breast cancer. The in situ hybridization detection kit for the HER-2 gene and the detection method have the advantages that: the kit provided by the invention has the characteristics of high sensitivity and high specificity; and the detection method of the invention is convenient and easy to operate, and can be commonly used and popularized in district-level above hospitals.

The invention discloses an in-situ hybridization detection kit, which comprises a hybridization probe and a marker, and further discloses a method utilizing the in-situ hybridization detection kit to detect the GADD45G (growth arrest and DNA-damage-inducible, gamma) gene RNA expression change, which is closely related with the pathologic evolution in the early stage of solid tumor. The method comprises the following steps: (1) under a condition that a hybridization probe and a target sequence can form a stable hybridization complex, contacting RNA to be detected in a substrate with a hybridization probe so as to form a hybridization complex; (2) detecting the obtained hybridization complex. The provided kit and detection method can detect the expression quantity of GADD45G gene in the RNA level, can detect the cancer in an earlier stage compared with the medical imaging technology and conventional clinical biochemical index detection, can achieve real RNA level screening in the early stage of canceration, moreover, have the advantages of simpleness, convenience, and low cost, and thus are convenient to promote and use in county/district hospitals.

The invention discloses an in-situ hybridization detection kit, which comprises a hybridization probe and a marker, and further discloses a method utilizing the in-situ hybridization detection kit to detect the GPR116 gene RNA expression change, which is closely related with the pathologic evolution in the early stage of cancer. The method comprises the following steps: (1) under a condition that a hybridization probe and a target sequence can form a stable hybridization complex, contacting RNA to be detected in a substrate with a hybridization probe so as to form a hybridization complex; (2) detecting the obtained hybridization complex. The provided kit and detection method can detect the expression quantity of GPR116 gene in the RNA level, can detect the cancer in an earlier stage compared with the medical imaging technology and conventional clinical biochemical index detection, can achieve real RNA level screening in the early stage of cancer, moreover, have the advantages of simpleness, convenience, and low cost, and thus are convenient to promote and use in county/district hospitals.

The invention relates to an in-situ hybridization detection kit of MAGEA3 (Melanoma-Associated Antigen Antiger 3), comprising a hybridization probe and a marker, wherein the hybridization probe sequence is shown in SEQ ID No.1. The invention also provides an in-situ hybridization detection method of the MAGEA3. In addition, the invention also provides application of the kit to the preparation of medicaments for detecting liver cancer diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity; and the detection method of the invention is convenient and simple for operation and can be widely used and popularized in municipal or higher-grade hospitals.

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and markers. The invention also discloses a method for applying the kit in in-situ hybridization detection of micro RNA-182 having a close relationship with pathological evolution of various cancers in an early stage, and the method comprises the following steps: (1) under the condition that the hybridization probe and a target sequence can form a stable hybrid complex, contacting RNA to be detected in a substrate with the hybridization probe so as to form a hybrid complex; (2) detecting the hybrid complex. The kit and the detection method provided in the invention can detect the expression level of micro RNA-182 at RNA level, enable detection indexes to be obtained at an earlier stage than medical imaging and conventional clinical biochemical detection do, and can realize genuine precancerous lesion RNA level screening; meanwhile, the detection method is simple and convenient, costs little and is convenient for popularization and application in county hospitals.

The invention relates to an in-situ hybridization detection kit of a DAXX (death associated protein) gene, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is as shown in SEQ ID NO.1. The invention also discloses an in-situ hybridization detection of the DAXX gene. In addition, the invention also provides an application of the kit in preparing drugs for detecting acute lymphoblastic leukemia. The invention has the advantage that the kit has the characteristics of high sensitivity and strong specificity. The detection method in the invention is convenient and simple in operation, and can be widely applied and popularized in district-level or city-level hospitals.

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses an in-situ hybridization detection method for microRNA-17-3p being closely related to the early pathologic evolution of various cancers by using the kit. The in-situ hybridization detection method comprises the following steps of: (1) under the condition that the hybridization probe and a target sequence can form a stable hybridization complex, leading RNA (Ribonucleic Acid) to be tested in a substrate to be in contact with the hybridization probe, and forming the hybridization complex; and (2) detecting the hybridization complex. The kit and the detection method provided by the invention can be used for detecting the expression quantity of the microRNA17-3p at the level of RNA, which is more early obtained in comparison with detection indexes of imaging medicine and the traditional clinical biochemistry, thereby the RNA level screening can be realized truly in the earlier stage of canceration, and simultaneously, the detection method provided by the invention is simple and convenient and low in cost and is convenient to popularize and apply in county-level hospitals.

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses an in-situ hybridization detection method for microRNA-143 being closely related to the early pathologic evolution of various cancers by using the kit. The in-situ hybridization detection method comprises the following steps of: (1) under the condition that the hybridization probe and a target sequence can form a stable hybridization complex, leading RNA (Ribonucleic Acid) to be tested in a substrate to be in contact with the hybridization probe, and forming the hybridization complex; and (2) detecting the hybridization complex. The kit and the detection method provided by the invention can be used for detecting the expression quantity of the microRNA17-143 at the level of RNA, which is more early obtained in comparison with detection indexes of imaging medicine and the traditional clinical biochemistry, thereby the RNA level screening can be realized truly in the earlier stage of canceration, and simultaneously, the detection method provided by the invention is simple and convenient and low in cost and is convenient to popularize and apply in county-level hospitals.

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses a method for in-situ hybridization detection of vascular endothelial cell's genetic factor (KLF4) gene's mRNA which is closely related with pathologic evolution of cardiovascular and cerebtovascular vascular endothelial injury in the earlier stage by the use of the kit. The method comprises the following steps: (1) under the condition that a hybridization probe and a target sequence can form a stable hybrid complex, RNA to be tested in a substrate is contacted with the hybridization probe so as to form a hybrid complex; and (2) the hybrid complex is detected. According to the detection kit and the detection method, gene expression quantity can be detected at the RNA level, the index of the detection method is ealier than present clinical biochemical detection index (protein detection index), and genuine RNA level screening of the earlier stage of cardiovascular and cerebtovascular disease can be realized. Meanwhile, the detection method provided by the invention is simple and convenient; cost is low; and the method is convenient for popularization and application in district-level hospitals.